stockrow
Friday 6 November 2026
Export CPIX’s income statement to Excel — free account
Cumberland Pharmaceuticals Inc.
CPIX Healthcare Drug Manufacturers Specialty & Generic
Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Revenue
- −98.5%
- EPS
- −480.0%
- Free cash flow
- −82.8%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
5.24
0.23
+4.59%
Follow CPIX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.10 | 1.16 | 1.33 | 1.13 | |
P/FCF ratio |
168.58 | 39.28 | 12.45 | 7.00 | |
P/Operating CF |
575.14 | 125.63 | 19,707.63 | 249.32 | |
P/B ratio |
5.68 | 2.28 | 2.41 | 1.81 | |
Price to Tangible BV |
5.69 | 6.40 | 2.41 | 4.73 | |
EV/Sales |
3.31 | 1.14 | 1.30 | 1.01 | |
EV/EBITDA |
0.00 | 0.00 | 42.88 | 0.00 | |
EV/Operating CF |
138.82 | 33.75 | 11.76 | 6.12 | |
EV/FCF |
179.83 | 38.74 | 12.21 | 6.27 | |
Quick Ratio |
0.49 | 0.73 | 0.77 | 1.05 | |
Current Ratio |
0.96 | 0.95 | 1.01 | 1.23 | |
Net Debt/EBITDA |
0.88 | 3.11 | (3.04) | (9.39) | |
Debt/Assets |
0.00% | 7.38% | 6.82% | 7.95% | |
Debt/Equity |
0.00 | 0.25 | 0.21 | 0.20 | |
Asset Turnover |
0.48 | 0.60 | 0.58 | 0.58 | |
Operating CF/Net income |
(0.04) | (0.12) | 0.00 | (0.10) | |
Capex/Depreciation |
0.02 | (0.01) | (0.04) | (0.02) | |
Interest Coverage |
(4,515.00) | (36.47) | 4.51 | (17.92) | |
Research and Development Expense of Revenue |
463.78% | 15.97% | 15.94% | 15.12% | |
Selling, General and Administrative Expense of Revenue |
1,530.09% | 83.44% | 107.37% | 84.49% | |
Intangible Assets out of Total Assets |
0.00 | 0.19 | 0.00 | 0.24 | |
Share Based Compensation of Revenue |
46.79% | 1.17% | 1.26% | 0.98% | |
Graham Net Nets |
(0.12) | (0.35) | (0.26) | (0.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.27%) | (15.08%) | (4.77%) | (7.69%) | |
Free Cash Flow Yield |
0.59% | 2.55% | 8.03% | 14.29% | |
Revenue per Share |
0.01 | 0.61 | 0.92 | 0.55 | |
Operating CF per Share |
0.01 | 0.03 | 0.00 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | 0.02 | 0.00 | 0.01 | |
Cash per Share |
0.26 | 0.74 | 0.77 | 1.02 | |
Shareholders Equity per Share |
1.14 | 1.42 | 1.65 | 1.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.14 | 1.42 | 1.65 | 1.72 | |
Free Cash Flow |
0.14 | 0.37 | (0.04) | 0.13 | |
Working Capital |
(1.55) | (1.70) | 0.32 | 5.63 | |
Capital Expenditures |
(0.03) | (0.02) | (0.04) | (0.05) | |
Net Current Asset Value |
(12.13) | (16.90) | (15.22) | (10.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.16 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.87 | 12.37 | 14.32 | 10.87 | |
Average Payables |
16.50 | 15.23 | 16.24 | 12.95 | |
Average Inventory |
1.63 | 4.78 | 2.01 | 3.72 | |
Average Assets |
65.39 | 70.47 | 76.20 | 71.32 | |
Average Common Equity |
22.39 | 24.82 | 23.55 | 25.14 |
Columns are period end dates · fundamentals updated 26 Oct 2026